脑部3D黑血MR图像上的迷路强化作为(肺)癌患者顺铂耳毒性的影像学生物标志物
该研究纳入2015年12月至2019年3月间96例连续肺癌患者,最终21例接受顺铂化疗并完成钆增强3D-BB、3D-T1W及T2W序列检查者入选。迷路强化组6例中,4例听力下降者均有耳蜗强化,5例有前庭强化者中4例有前庭症状;3D-T1W未见强化。作者认为3D-BB上迷路强化伴迷路内液体信号正常可作为顺铂耳毒性的影像学生物标志物,不应误认为迷路内转移。
要点
- 3D-BB序列可显示顺铂相关迷路强化,而3D-T1W序列未见强化。
- 听力下降患者表现为耳蜗强化,前庭症状患者表现为前庭/半规管强化。
- 迷路内液体T2W信号正常可排除迷路内转移,支持耳毒性诊断。
关键影像表现/征象
- 所有患者3D-T1W图像均未见强化区域,T2W图像迷路内液体均呈高信号,排除转移。
- 迷路强化组6例中,耳蜗和半规管是最常受累区域。
- 迷路强化组中4例听力下降者均可见耳蜗强化;听力正常者无耳蜗强化。
- 迷路强化组6例中5例可见前庭强化,其中4例有前庭症状。
临床应用与阅片要点
- 作者认为,在迷路内液体信号正常时,3D-BB图像上的迷路强化可在日常临床实践中作为顺铂毒性的影像学生物标志物。
- 作者指出,3D-BB图像上的迷路强化不应被误认为迷路内转移。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Cancer patients treated with platinum-based chemotherapy can present with ototoxicity symptoms. The purpose of this work is to report the imaging features related to cisplatin ototoxicity.
METHODS: Between December 2015 and March 2019, a cohort of 96 consecutive patients with lung cancer was selected. Only patients who received cisplatin chemotherapy and underwent an imaging protocol consisting of a Gd-enhanced 3D-BB and 3D-T1W sequence, as well as T2W sequence to exclude metastases, were included. Labyrinthine enhancement was assessed, and all findings regarding the auditory and vestibular function were retrieved from the clinical files.
RESULTS: Twenty-one patients met the inclusion criteria. The Gd-enhanced 3D-BB images were used to divide them into the labyrinth enhancement group (LEG) and the labyrinth non-enhancement group (LNEG). None of these patients demonstrated enhancing regions on the 3D-T1W images. The labyrinthine fluid remained high on the T2 images in all patients, excluding metastases. The LEG consisted of 6 patients. The cochlea and semicircular canals were the most frequently affected regions. All the LEG patients that presented with hearing loss (4/6) had cochlear enhancement. Patients with normal hearing had no cochlear enhancement. Five patients (5/6) showed vestibular enhancement. Four of these patients had vestibular symptoms.
CONCLUSION: Labyrinthine enhancement as an imaging feature related to cisplatin ototoxicity is unreported. This study demonstrates a correlation between hearing loss and cochlear enhancement and also between vestibular impairment and vestibular/semicircular enhancement on 3D-BB images, which remained invisible on the 3D-T1W images. The labyrinthine enhancement on 3D-BB images in the presence of normal signal intensity of the intralabyrinthine fluid can be used as an imaging biomarker for cisplatin toxicity in daily clinical practice and should not be mistaken for intralabyrinthine metastases.
引用
- Veiga M, Kuhweide R, Demaerel V, et al. Labyrinthine enhancement on 3D black blood MR images of the brain as an imaging biomarker for cisplatin ototoxicity in (lung) cancer patients. Neuroradiology. 2020. PMID: 32761280. doi:10.1007/s00234-020-02504-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。